Form 4: Teva EVP Shields Granted 33,424 Restricted Share Units

Teva Pharmaceutical Industries Ltd.'s EVP of Global Operations, Matthew Shields, was granted 33,424 restricted share units with a multi-year vesting schedule.

Summary

• Matthew Shields, Teva Pharmaceutical Industries Ltd.'s (TEVA) EVP, Global Operations, was granted 33,424 Restricted Share Units (RSUs).
• The RSUs were granted on March 4, 2026, and are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• These units will vest in four equal annual installments of 8,356 units each, commencing on March 4, 2027, and continuing through March 4, 2030.
• Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
• The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices designed to align management incentives with long-term company performance and retention.

Positives

• The grant of Restricted Share Units to a key executive like Matthew Shields aligns his interests with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention and sustained performance over several years.

Future Outlook

The multi-year vesting schedule for the granted Restricted Share Units indicates an expectation of continued executive tenure and performance through at least March 2030, aligning executive incentives with the company's long-term strategic goals.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Share Units with multi-year vesting, are a standard component of executive compensation packages in the pharmaceutical industry. This practice is common among peers like Pfizer, Johnson & Johnson, and Novartis, aiming to incentivize long-term performance and executive retention.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) as a compensation tool for executives is a widely adopted practice across the global pharmaceutical industry, consistent with companies such as Pfizer, Merck, and AstraZeneca.
• A four-year vesting schedule, with annual installments, is a common structure designed to align executive incentives with long-term shareholder value and promote retention, similar to programs observed at major pharmaceutical firms.
• The grant of 33,424 RSUs to an EVP of Global Operations is within the typical range for senior executives at a company of Teva's size and market capitalization, reflecting standard industry compensation benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased executive alignment with long-term company performance and retention.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices for senior leadership.

Next Steps

• Vesting of 8,356 Restricted Share Units on March 4, 2027.
• Vesting of 8,356 Restricted Share Units on March 4, 2028.
• Vesting of 8,356 Restricted Share Units on March 4, 2029.
• Vesting of 8,356 Restricted Share Units on March 4, 2030.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a senior executive, which is a standard component of executive compensation. While it signals continued executive commitment and aligns interests with long-term performance, it does not present new information that would fundamentally alter the investment thesis for Teva Pharmaceutical Industries Ltd. Therefore, a 'hold' recommendation is appropriate as this event alone is not a catalyst for significant price movement.

Keywords

Teva Pharmaceutical Industries, TEVA, Matthew Shields, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance